Little Green Pharma Ltd (ASX: LGP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Little Green Pharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Little Green Pharma Ltd (ASX: LGP)
Latest News
Cannabis Shares
Why are these 2 ASX cannabis stocks sputtering today?
Cannabis Shares
Could ASX cannabis shares be set for a resurgence?
Cannabis Shares
Why ASX cannabis shares just jumped back into the spotlight
Cannabis Shares
Little Green Pharma share price shoots 13% higher after capital raise
Cannabis Shares
Why did this ASX cannabis share just rocket 46%?
Cannabis Shares
Why are these 2 ASX cannabis shares booming all of a sudden?
Cannabis Shares
Little Pharma shares lift 8% amid appointment of 'highly regarded' director
Cannabis Shares
Why did the Little Green Pharma share price flame 23% higher today?
Cannabis Shares
ASX cannabis shares in spotlight amid COVID prevention research
Share Gainers
Why is the Little Green Pharma (ASX:LGP) share price in the green today?
Cannabis Shares
Little Green Pharma (ASX:LGP) share price leaps 7% on revenue growth
Healthcare Shares
How did ASX healthcare shares perform in the FY22 first quarter?
LGP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Little Green Pharma Ltd
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). The company offers LGP-branded medicinal cannabis oil products in the Australian and European markets.
LGP Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Mar 2024 | $0.14 | $0.01 | 7.69% | 408 | $0.14 | $0.14 | $0.13 |
26 Mar 2024 | $0.13 | $-0.01 | -7.14% | 106,030 | $0.14 | $0.14 | $0.13 |
25 Mar 2024 | $0.14 | $0.02 | 16.00% | 363,518 | $0.13 | $0.14 | $0.13 |
22 Mar 2024 | $0.13 | $-0.01 | -7.69% | 212,458 | $0.13 | $0.13 | $0.13 |
21 Mar 2024 | $0.13 | $0.01 | 8.00% | 80,579 | $0.13 | $0.13 | $0.13 |
20 Mar 2024 | $0.13 | $0.00 | 0.00% | 149,226 | $0.13 | $0.13 | $0.13 |
19 Mar 2024 | $0.13 | $0.00 | 0.00% | 115,124 | $0.13 | $0.13 | $0.13 |
18 Mar 2024 | $0.13 | $0.00 | 0.00% | 88,955 | $0.13 | $0.13 | $0.13 |
15 Mar 2024 | $0.13 | $0.00 | 0.00% | 95,875 | $0.13 | $0.13 | $0.12 |
14 Mar 2024 | $0.13 | $-0.01 | -7.69% | 33,399 | $0.13 | $0.13 | $0.13 |
13 Mar 2024 | $0.13 | $0.01 | 8.00% | 68,903 | $0.13 | $0.13 | $0.13 |
12 Mar 2024 | $0.13 | $-0.01 | -7.69% | 28,911 | $0.13 | $0.13 | $0.13 |
11 Mar 2024 | $0.13 | $0.01 | 8.00% | 466,567 | $0.13 | $0.13 | $0.13 |
08 Mar 2024 | $0.13 | $-0.01 | -7.69% | 641,075 | $0.13 | $0.13 | $0.13 |
07 Mar 2024 | $0.13 | $0.00 | 0.00% | 228,402 | $0.14 | $0.14 | $0.13 |
06 Mar 2024 | $0.13 | $0.00 | 0.00% | 72,609 | $0.14 | $0.14 | $0.13 |
05 Mar 2024 | $0.13 | $0.00 | 0.00% | 183,899 | $0.14 | $0.14 | $0.13 |
04 Mar 2024 | $0.13 | $0.00 | 0.00% | 45,717 | $0.14 | $0.14 | $0.13 |
01 Mar 2024 | $0.13 | $0.00 | 0.00% | 35,892 | $0.14 | $0.14 | $0.13 |
29 Feb 2024 | $0.13 | $0.00 | 0.00% | 136,822 | $0.14 | $0.14 | $0.13 |
28 Feb 2024 | $0.13 | $-0.02 | -13.79% | 334,175 | $0.15 | $0.15 | $0.13 |
27 Feb 2024 | $0.15 | $0.02 | 15.38% | 152,992 | $0.14 | $0.15 | $0.14 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
27 Sep 2023 | Neale Fong | Issued | 70,000 | $11,200 |
Issue of securities. 140,000 Retention Share Rights
|
27 Sep 2023 | Angus Caithness | Issued | 1,000,000 | $160,000 |
Issue of securities. 40,32,000 Performance Rights
|
27 Sep 2023 | Fleta Solomon | Issued | 277,777 | $49,999 |
Placement.
|
27 Sep 2023 | Fleta Solomon | Issued | 1,000,000 | $160,000 |
Issue of securities. 40,36,000 Rights, As per announcement on 04-10-2023
|
27 Sep 2023 | Michael Lynch-Bell | Issued | 140,000 | $22,400 |
Issue of securities. 280,000 Retention Share Rights
|
27 Sep 2023 | Beatriz Banzo | Issued | 70,000 | $11,200 |
Issue of securities. 2,20,000 Rights
|
07 Jul 2023 | Angus Caithness | Issued | 11,870 | $2,967 |
Director remuneration. deemed issue price
|
07 Jul 2023 | Michael Lynch-Bell | Issued | 18,459 | $4,374 |
Director remuneration. deemed issue price
|
07 Jul 2023 | Neale Fong | Issued | 9,251 | $2,192 |
Director remuneration. deemed issue price
|
30 Jun 2023 | Angus Caithness | Transfer | 3,500,000 | $542,500 |
Off-market transfer.
|
30 Jun 2023 | Angus Caithness | Transfer | 3,500,000 | $542,500 |
Off-market transfer.
|
24 Apr 2023 | Neale Fong | Issued | 143,453 | $33,998 |
Director remuneration. deemed issue price
|
24 Apr 2023 | Angus Caithness | Exercise | 32,000 | $5,440 |
Conversion of securities. 3,032,000 Rights
|
24 Apr 2023 | Angus Caithness | Issued | 228,629 | $57,157 |
Director remuneration.
|
24 Apr 2023 | Angus Caithness | Issued | 32,000 | $5,440 |
Conversion of securities.
|
24 Apr 2023 | Michael Lynch-Bell | Issued | 286,248 | $67,840 |
Director remuneration. deemed issue price
|
24 Apr 2023 | Fleta Solomon | Issued | 34,000 | $5,780 |
Conversion of securities. As per announcement on 01-05-2023, NOC is conversion of vested share rights but there is no change in post holdings of rights.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Neale William Fong | Non-Executive Director | Nov 2018 |
Dr Fong is a registered medical practitioner with over 35 years in senior leadership roles in private hospitals, the public health systems, management consulting, academia, health research, aged care and not for profit organisations. Neale is currently CEO of Bethesda Health Care and formerly was Director General of the West Australian Department of Health. Neale is an ASX company director and is currently independent chair of Intelicare. He is a former nonexecutive director of Neurotech International and executive chair of Chrysalis Resources and has been a Fellow of the Australian Institute of Company Directors since 2001. Neale is also Chair of the Company's Risk Committee.
|
Mr Angus McDougall Caithness | Executive Director | Feb 2018 |
Mr Caithness is a corporate finance executive and consultant in Australia and international markets. Angus has ASX experience as a non-executive Director of Lindian Resources CFO of Hunnu Coal and Company Secretary for the IPO of Haranga Resources. Following these roles, Angus acted as CFO of Tavan Tolgoi, the owner of the coking coal deposit looking at a US$10bn dual listing in London and Hong Kong prior to the change in the Mongolian government.
|
Ms Fleta Jennifer Solomon | Chief Executive OfficerManaging Director | May 2017 |
Ms Solomon drives the strategic vision of the business and as Chief Executive Officer of Little Green Pharma has grown the company from a medicinal cannabis startup to an industry medicinal cannabis brand in Australia and overseas. Fleta has 20 years of experience in corporate and consumer health markets.
|
Mr Michael David Lynch-Bell | Non-Executive ChairmanNon-Executive Director | Nov 2018 |
Mr Lynch-Bell is a corporate finance executive and consultant. Michael was appointed on 13 November 2018. His early Ernst and Young career were focused on auditing clients within the oil and gas sectors and later added mining to his portfolio. Michael also led Ernst and Young's UK IPO and Global Natural Resources transaction teams in the Transaction Advisory practice. He has been involved advising companies on fundraising, re-organizations, transactions, corporate governance as well as IPOs.
|
Ms Beatriz Vicen Banzo | Non-Executive Director | Jul 2022 |
Ms Banzo Has over 30 years working in the European pharmaceutical industry, Beatriz is an experienced and decorated expert in European pharmaceutical regulatory and quality assurance matters. Prior to joining LGP, Beatriz was the Director of Public Affairs (Market Access and Patient Advocacy), Regulatory and Quality Assurance for Bayer Pharmaceuticals and Consumer Health in Spain, Head of Regulatory Affairs and Permanent Executive Committee Guest at Novartis Pharmaceutical Company.
|
Mr Alistair Warren | Company Secretary | Jul 2020 |
-
|
Alistair Warren | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 37,923,854 | 12.69% |
Ubs Nominees Pty Ltd | 32,256,846 | 10.79% |
Ms Fleta Jennifer Solomon | 21,559,439 | 7.20% |
Barbright Australia Pty Ltd <Interquartz Super A/C> | 14,420,420 | 4.82% |
Banquo Consulting Pty Ltd | 9,048,000 | 3.02% |
Bnp Paribas Noms Pty Ltd <Drp> | 7,468,464 | 2.50% |
Cg Nominees (Australia) Pty Ltd | 4,147,061 | 1.39% |
Superhero Securities Limited <Client A/C> | 3,728,338 | 1.25% |
Benoni Pty Ltd <The Mkj Super Fund A/C> | 3,582,127 | 1.20% |
Citicorp Nominees Pty Limited | 2,530,219 | 0.85% |
Paul Frederick Long <The Long A/C> | 2,371,691 | 0.79% |
Mr Angus Caithness | 2,239,571 | 0.75% |
Ms Jenny Lorraine Mckay <J & K Mckay | 2,229,746 | 0.75% |
Mr Damien Matthew Booth <Damien Booth Family A/C> | 1,858,639 | 0.62% |
Jasforce Pty Ltd | 1,705,556 | 0.57% |
Michael D Lynch-Bell | 1,669,991 | 0.56% |
Mr Sean Edward Reid plus Ms Louise Jane Pilkington | 1,552,600 | 0.52% |
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 1,406,174 | 0.47% |
Jensen Jarrah Pty Ltd | 1,369,231 | 0.46% |
Ms Mary Bernadette Davis | 1,240,000 | 0.41% |